Compounds > rsu 1131
Page last updated: 2024-12-07

rsu 1131

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RSU 1131: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100186
CHEMBL ID122470
MeSH IDM0149044

Synonyms (14)

Synonym
brn 5817730
1h-imidazole-1-ethanol, alpha-((2-methyl-1-aziridinyl)methyl)-2-nitro-
rsu-1131
nsc 358270
rsu 1131
88876-89-5
nsc-358270
nsc358270
1-(2-methylaziridin-1-yl)-3-(2-nitro-1h-imidazol-1-yl)propan-2-ol
CHEMBL122470
1-(2-methylaziridin-1-yl)-3-(2-nitroimidazol-1-yl)propan-2-ol
1-(2-nitro-1-imidazolyl)-3-(2-methyl-1-aziridinyl)-2-propanol
DTXSID001008544
AKOS040753842
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID217042Selective toxicity to hypoxic V79-379A cells was determined in vitro; expressed as concentration required to give enhancement ratio of 1.61992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
AID231785Ratio of concentration required to kill 50% aerobic V79-379A cells C50(air) to that of concentration required to kill 50% of cells under N2 C50(N2) was determined1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
AID217044Concentration required to kill 50% of aerobic V79-379A cells (in vitro)1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
AID217043Concentration required to kill 50% of V79-379A cells under N2 (in vitro)1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.60 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		1.9810C-nitro compound;
imidazoles		antitubercular agent
methionine sulfoximine
methionine sulfoximine : A non-proteinogenic alpha-amino acid that is the sulfoximine derivative of methionine .		1.9810methionine derivative;
non-proteinogenic alpha-amino acid;
sulfoximide
buthionine sulfoximine
Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.		1.9810diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
misonidazole
Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.		2.8940
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol: structure given in first source		3.0750
1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol
[no description available]		1.9710
rb 7040
[no description available]		1.9710
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		1.98102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
ConditionIndicatedRelationship StrengthStudiesTrials